Price (pre-market ~76.69) is below the pivot (78.448) and only slightly above S1 (76.349): the stock is in a near-support “decision zone,” not a clean breakout.
Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating the bigger trend remains up.
MACD histogram is negative (-0.172) and expanding: bearish momentum is building in the short term.
RSI(6) ~53.45: neutral, no oversold bounce signal.
Levels to watch:
Support: 76.35 (S1), then 75.05 (S2)
Resistance: 78.45 (pivot), then 80.55 (R1)
Pattern-based forward odds skew slightly negative: ~-4.46% over the next week (per provided similarity analysis).
Volatility: IV (30d) ~51.44 vs HV ~57.05; IV rank ~11 and percentile ~33 suggest options are not priced at extremes (not “panic” expensive).
Activity: today’s option volume is relatively light (1,793 contracts) and below typical recent averages (today vs 30d avg volume ~65.63), so the signal is more about skew than intensity.
Technical Summary
Sell
8
Buy
5
Positive Catalysts
Upcoming earnings (QDEC 2025 on 2026-02-
can act as a catalyst if guidance/launch metrics surprise to the upside.
Neutral/Negative Catalysts
Short-term momentum deterioration (negative and expanding MACD histogram) increases odds of a support break.
Price is currently below the pivot; failure to reclaim ~78.45 soon keeps the near-term technical posture weak.
Event risk: earnings on 2026-02-19 after hours could produce a sharp move; with no recent news, expectations may be more sensitive to any metric miss.
Trading trends: hedge funds and insiders are “Neutral,” offering no confirming accumulation signal.
No recent news flow in the last week: fewer near-term narrative drivers to reverse the current momentum.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $120.7M, +4318.01% YoY (very strong growth, consistent with a commercialization step-change).
Net income: -$182.7M, improved +12.78% YoY (losses narrowing but still meaningfully negative).
EPS: -0.95, improved +10.47% YoY.
Gross margin: 94.56%, up 21.06% YoY (high margin profile; supports scalability if revenue continues to ramp).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: targets have generally moved up and coverage is positive (Buy/Overweight/Outperform bias).
Key changes:
2026-02-03: BofA raised PT to $88 (Buy).
2025-12-15: Leerink raised PT to $86 (Outperform).
2025-11-11: Wells Fargo raised PT to $84 (Overweight).
2026-01-27: Barclays initiated Overweight with a notably high PT of $157.
Wall Street “pros” view: upside to 2026 estimates (Attruby ramp), improving fundamentals, and biotech tailwinds.
Wall Street “cons” view (from coverage notes): payer/reimbursement and patient-add pace monitoring; competitive landscape concerns in oncology/KRAS (noted in BridgeBio Oncology initiation commentary).
Influential/political trading: No recent congress trading data available; insider trading trend provided as neutral.
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 63.730
Low
69
Averages
87.63
High
100
Current: 63.730
Low
69
Averages
87.63
High
100
BofA
Jason Zemansky
Buy
maintain
$85 -> $88
AI Analysis
2026-02-03
Reason
BofA
Jason Zemansky
Price Target
$85 -> $88
AI Analysis
2026-02-03
maintain
Buy
Reason
BofA analyst Jason Zemansky raised the firm's price target on BridgeBio to $88 from $85 and keeps a Buy rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings "may not have the same impact they've had in prior years," the analyst tells investors in a preview for the firm's biopharma coverage.
Barclays
initiated
$157
2026-01-27
Reason
Barclays
Price Target
$157
2026-01-27
initiated
Reason
Barclays initiated coverage of BridgeBio with an Overweight rating and $157 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBIO
